Observational Study on The Safety of Niraparib in Ovarian Cancer

Observational Study on The Safety of Niraparib in Ovarian Cancer Observational Study The Safety of Niraparib in Ovarian Cancer Protocol Table of Contents Abbreviations............................................................................................................... [...] We will describe the cohort’s baseline clinical and demographic characteristics and identify the first instance of thrombocytopenia, neutropenia, and anemia during treatment using administrative data in Ontario, a combination of administrative data and electronic medical records in British Columbia and Alberta, and registry data in Quebec from the Personalize My Treatment Registry. [...] Observational Study Protocol: The Safety of Niraparib in Ovarian Cancer 5 Background and Rationale Ovarian cancer may present in the ovaries, the fallopian tubes, or the peritoneum. [...] Policy Question How does the safety and tolerability of niraparib in the real world compare with observations from the seminal clinical trials? Policy Impact The findings of the query will be used to support a risk-benefit analysis of the use of niraparib in patients with ovarian cancer given the reported toxicity. [...] Observational Study Protocol: The Safety of Niraparib in Ovarian Cancer 31 Observational Study The Safety of Niraparib in Ovarian Cancer Project Team Ontario Alberta British Columbia Quebec Abbreviations Amendments and Updates Abstract Background and Rationale Policy Issue Policy Question Policy Impact Research Question Objectives Research Methods Study Design Study Population and Setting Study Va.